Volume -12· Issue No. - 10 October 2026

Microbioz India

www.microbiozhealth.com

Healthcare Special Edition



EXCLUSIVE FEATURE

Where Diagnostics Meets the Future of Healthcare

Advancing Precision, Empowering Decisions, Transforming Lives

BREAKING NEWS

Park Hospital Marks Groundbreaking

Rs. 200 Crore, 550-Bed Multi-Super-Speciality Hospital in Prayagraj

COVER STORY

INNOVATION THAT HEALS

The New Era of Healthcare

Transforming Patient Care Through Medical Technology, Precision Diagnostics and Connected Healthcare

HEALTHCARE PIONEER

Dr. N. Murugesan

Introduces 'Blue Nephrology', a Prevention-First Approach to Kidney Health in Puducherry

RNI:UPENG/2017/3675

Price:100/-



Human connections

We know that quality, reliability, and trust are of paramount importance in medical technology. This is why our precision drive systems are not only used in insulin pumps, surgical robots, and prostheses, but also in implantable systems.
medical.maxongroup.com

Precision Drive Systems

maxon

Scan QR Code to visit our website

ISO 13485:2016
ICMED 13485

www.jmitra.co.in

PRESERVING HUMAN LIFE



Proud to be a
GREAT PLACE TO WORK® CERTIFIED™
For The 4th Consecutive Year.

Great Place To Work. Certified JAN 2026-JAN 2027 INDIA

Since 1969

J. Mitra & Co. Pvt. Ltd.

.....a vision to serve mankind™

- Rapid Test Kits
- Elisa Test Kits
- Blood Grouping Sera
- FIA Test Kits
- Chemiluminescence (CLIA) Test Kits
- Medical Analyzers & Instruments

E-mail: jmitra@jmitra.co.in

Tel.: +91-11-471-30-300


CE FDA NSIC CERTIFIED CO. ISO 13485 Quality Management System ISO 9001:2008

YORCO®

FACTUAL LEGACY SINCE 1964

YORCO Grossing Station

EVOLVE YOUR LAB WITH ADVANCE TECHNOLOGY



- High performance airflow
- Negative pressure air curtain/air flap
- Unique top fume catchment slots
- Crucially designed
- Ease of Use
- Integral Ventilation
- UV Disinfection
- Simplified controls
- Under Table tub wash

Model: YSI-222 Ex

YORCO®

YORK SCIENTIFIC INDUSTRIES PRIVATE LIMITED

Laboratory Equipment & Instruments

+91-1204741800

www.yorco.co.in

sales@yorco.co.in


UNIMEDITREK
UNIVERSAL GUIDANCE TOWARDS A HEALTHY FUTURE

UNIMEDITREK KSHRIOM SERIES VTP 300

Finer Specimen Processing on Each Run!

Kshriom Series Fully Automated Vacuum Tissue Processor

CE | ISO 9001:2015 | ISO 13485:2016 | FDA





UPCOMING

UNIMEDITREK PRIVATE LIMITED
14 Chitra vihar,New Delhi-110092, India
Mob: +91-9810533445 | **Email:** sales@unimeditrek.com | **Website:** www.unilabequipments.com


TABLE OF CONTENTS











Cover Story 10

Innovation that Heals: The new era of Healthcare:Transforming Patient Care Through Medical Technology, Precision Diagnostics and Connected Healthcare

Featured Article 15

Where Diagnostics meets the future of Healthcare

Business News 19

Park Hospital Marks Groundbreaking of Rs. 200 Crore, 550-Bed Multi-Super-Speciality Hospital in Prayagraj

Product Launches 41

Leica Biosystems Launches Laser Cassette Printer for Histology Labs

Ami Polymer

Enabling Healthcare

BRONZE | Top 35% ecovadis Sustainability Rating MAR 2026

Great Place To Work. Certified INDIA

BEYOND THE TUBE

Why Respiratory Circuit Design Matters in Healthcare

ImaBreath™ reusable silicone ventilator circuit tubes are developed for ventilator and respiratory applications. Ami Polymer lists features including flexibility, kink resistance, high tensile strength, customisable connectors and suitability for steam, ethylene oxide (ETO) or gamma sterilisation, subject to the product's specified requirements. Configurations are listed for neonatal, paediatric and adult applications. The correct size and configuration must be matched to the intended equipment and its requirements.

Benefits

- Reduces Microbial Growth
- Enhanced Serializability
- Improved Humidification Control
- Customizable & Leak-Resistant Connections

Applications

- Mechanical ventilators (invasive and non-invasive)
- CPAP/BiPAP machines
- Anesthesia machines
- High-flow oxygen therapy systems

In respiratory care, attention to component design supports the reliability of the larger system-and helps clinical teams work with equipment suited to its intended purpose.





www.amipolymer.com
media@amipolymer.com

Our Staff.

Editor in Chief: Jeetendra Kumar Shukla

Head Business Development	Shubh Shrivastava
Technical Advisor	S.T.Ram
Digital Designing	Jeetendra Kumar
Interview & Meetings	Nimi Vashistha
International Sales	Devashish
Chief International Representative	Rebbeca Scolastica Bello
Nigeria Outreach	Sivashankari Ramamoorthi
Malaysia Outreach & Author	Rodel Estadillo Alo
Philippines Outreach	Dr.Moslim
Iraq outreach	Taylor Francis

Corporate Office:
Microbioz India
H1/204, Vikramaditya Tower, Alaknanda Market | Kalka Ji,
New Delhi - 110019, India
Mob:- +91-9670704431 | Tel:- +91-11-44459687
Email ID : support@microbiozindia.com

Registered with Registrar of News
Paper for India with RNI No:
UPENG/2017/73675

Owned, Printed, Published and Edited by Jitendra Kumar Shukla, printed at Ganapathi Overseas 1/63 Bahar-e -Sahara State Janki Puram Lucknow-226021, and Published from 631/63, Surendra Nagar, Mulayam Nagar, Chinhat - Lucknow-226016, Editor, Jitendra Kumar Shukla

Disclaimer:
Neither the **Microbioz India** nor its publishers nor anyone else involved in creating, producing or delivering the Microbioz India (in printed, web or CD format) or the materials contained therein, assumes any liability or responsibility for the accuracy, completeness, or usefulness of any information provided in the Microbioz India Magazine (in printed, web or CD format), nor shall they be liable for any direct, indirect, incidental, special, consequential or punitive damages arising out of the use of the Microbioz India magazine.

Editor's Word

Dear Readers,

Welcome to the latest issue of Microbioz India- Healthcare and Diagnostic special edition. It's a true pleasure to have you with us once again, and we hope you find this edition as captivating and inspiring as ever.

In this issue, we're thrilled to delve into the intriguing world of "**Innovation that Heals: The new era of Healthcare: Transforming Patient Care Through Medical Technology, Precision Diagnostics and Connected Healthcare**" our cover story of the month. Our team has worked tirelessly to curate content that we believe will both entertain and enlighten you, from thought-provoking features to stunning visuals that capture the essence of our chosen theme.

We are excited to showcase some incredible contributors, whose expertise and creativity have graced the pages of this magazine. Their passion for digital healthcare and innovation shines through in every article, photograph, and piece of art.

Be sure to check out our special product showcase section, where you'll find latest product launches and stories. It's a testament to our commitment to providing you, our readers, with diverse and engaging content.

As always, Microbioz India is a reflection of our dedication to delivering top-quality journalism, exquisite design, and stories that resonate with you. We're immensely grateful for your continued support and readership, which drives us to keep raising the bar.

We encourage you to connect with us through our social media channels, where you can share your thoughts, feedback, and suggestions. Your voices are what inspire and guide us in our mission to bring you a magazine that truly speaks to your interests and passions.

Thank you for choosing to spend your time with us. We hope you thoroughly enjoy this issue and that it leaves you inspired, informed, and entertained.

Enjoy the read!

Kumar Jeetendra

Microbioz India.

Magazine Publishing Company

Medicall
hospital needs expo

A-Z of Your Hospital Requirements



VISIT

Medicall

INDIA'S LARGEST & NO.1 HEALTHCARE EVENT
& HOSPITAL NEEDS EXHIBITION

MUMBAI

49th Edition | DEC 2026

TUE	WED	THU
8	9	10

HALL 4
NESCO

For enquiries: +91 7305 789 789 | www.medicall.in | info@medicall.in

Innovation That Heals: The New Era of Healthcare

Transforming Patient Care Through Medical Technology, Precision Diagnostics and Connected Healthcare



The interplay of medicine, technology, and science has changed the landscape of how we diagnose and treat disease. Innovations in medical technology touch upon many aspects of the healthcare continuum including the prevention, diagnosis, treatment, and monitoring of disease. The integration of transformative technologies is focused on allowing the industry to 'catch-up' with increasing patient demand and expectations, while better responding to the needs of an aging and more chronic-disease focused patient population.

There is a transition away from reactive care to proactive, predictive, preventive, and personalized care.

The use of novel technologies is revolutionizing patient care.

The digitization of clinical records is enabling more effective and timely information sharing among members of the healthcare team and across the care continuum.

The same digitization is expanding the means by which healthcare services and interventions are delivered, from the traditional clinic and hospital based settings, to the community and patient home.

Meanwhile, in the medical field, the use of AI to analyze complex information and assist with risk identification is helping healthcare workers find better ways to manage their time and increase efficiency.

AI can be used to help increase the quality of service offered and the decisions made within the field.

The advancement of digital healthcare relies on a number of key factors beyond the realm of technology. Chief among these are the safety of personal data, the seamless connection of various systems, and universal access. Technology should be used to enhance the relationship that healthcare workers have with their patients rather than replace the human element that is the most essential part of quality care.

Artificial Intelligence: A New Frontier in Medical Science

AI is revolutionizing medicine. It's impact will be as big, if not bigger, than the impact of the computer. This technology will be used to better diagnose and treat patients and improve efficiency in medical research and drug discovery, hospital management, and overall population health.

One example of this is using AI in medical imaging. It's also being used in pathology to analyze scanned tissue. There are so many opportunities and areas for improvement for working with AI in medicine. It will help improve the efficiency of medical care and help create a more proactive rather than reactive system. While some suggest the benefit of AI exceeds its risk, all AI tools in healthcare require human judgement to verify their output against clinical evidence and the data quality.

The factors that represent bias in training datasets, including generalizability, transparency and accountability, continue to be important in determining trust in the technology. The future of AI in healthcare depends on its responsible, prudent and collaborative implementation with clinicians.

Precision Medicine: Treatment Designed Around the Individual

In the field of healthcare, there is a drive towards individualized, precision treatments. This builds on the existing strategy of identifying homogenous groups to inform a broad treatment protocol. In this regard, precision medicine takes into account an individual's unique characteristics, differences in genes and the biology of the disease, as well as social and environmental factors.

There have been rapid advances in molecular diagnostics and biomarker research. Enhanced genomics and laboratory testing have played an increasingly important role in providing healthcare practitioners the tools to better understand the biology of a patient's disease and subgroup it accordingly. This knowledge can help inform selection of the most appropriate treatment for the patient.

In oncology, molecular diagnostics can aid in identifying underlying genetic alterations and inform drug choices. Pharmacogenomics can help understand the relationship between variations in a patient's genomic makeup and their response to treatment.

There is an increasing merge of diagnostics and therapeutics. This has important implications for modern healthcare and the goal of providing the right treatment to the right patient at the right time.

Diagnostic: The Backbone of Better Healthcare Choices

All effective healthcare plans rely on accurate diagnostic information.

Laboratories and diagnostic technology providers help healthcare professionals identify diseases, monitor treatment and counsel in public health.

There are innovations in diagnostic technology and workflows. There are new methods of diagnostic analysis and greater integration between the various systems that help healthcare workers make decisions with greater confidence.

The usage of point-of-care diagnostics is growing, especially when immediate clinical decisions depend on the results. Similarly, the use of polymerase chain reaction (PCR) and other molecular technologies to diagnose infections has increased.

Laboratory automation is another growing field. Automation of sample processing and analysis, combined with intelligent workflow systems, have decreased the need for personnel to perform repetitive, manual tasks. It is important to note that, though automation has made laboratories more flexible and responsive, there are still many traditional quality systems and processes that help ensure integrity and reliability of laboratory test results.

As prevention and individualized medicine becomes more prevalent, the role of diagnostics in medicine will also increase.

Medical Devices: Engineering Better Clinical Outcomes

New materials and combination of multiple technologies (such as, engineering, electronics, software, and others) have enabled rapid evolution of medical devices. There is a wide array of new devices across the entire medical spectrum. From imaging systems and patient monitors to instruments and devices for minimally-invasive surgery to smart infusion devices, medical devices have expanded the scope of healthcare professionals. Certain procedures can benefit from the use of robotic-assisted systems, and minimally invasive systems can help to reduce surgical trauma.

Some systems allow for continuous monitoring of vital signs, and can help to identify changes that might require clinical intervention.

There are ongoing developments in the integration of medical devices with healthcare systems. Wireless communications, secure data transfer, and aligned clinical practices can facilitate remote monitoring and management of patients.

Due to the increased pace of healthcare technology development, it is important for manufacturers to strengthen design and risk management processes. These processes can be effectively integrated within the product development life cycle. Strong controls and risk management processes throughout the product life cycle will help to balance the benefits to the patient against the risks that can be introduced by the technology.

Changes in Emphasis in Healthcare

One of the major changes in healthcare is the increased focus on preventing disease as opposed to just treating disease once symptoms arise.



Various technological advances have enabled the identification of populations at risk for developing a certain health condition, and helped healthcare professionals provide timely evaluation and intervention to those individuals. Examples of such technologies include population health analytics and remote monitoring. Effective management of follow up care, adherence to treatment, and lifestyle changes can be achieved through digital platforms. The analysis of the data can also help health systems understand the burden of disease and the usage of their health services.

Effective prevention of disease and promotion of health is accomplished through a multifaceted approach which includes strong primary healthcare, active and receptive vaccination, risk factor prevention, early diagnosis, and timely treatment. Other enablers include the right policies, engaged communities, and appropriate use of new technologies.

While predictions can be used to assess the likelihood that a given individual will develop a certain health condition or experience a clinical event in the future, and help identify individuals that require close surveillance, it is important to keep in mind that all predictions are not certain. Also, the clinical value of a prediction depends on the accuracy, availability and type of the intervention that can be provided to a patient.

A prevention-oriented healthcare system is likely to decrease avoidable adverse health events, improve quality of life and optimize the use of the limited health system resources.

Smart Hospitals and Connected Healthcare Ecosystem

The use of integrated digital systems by hospitals has increased in order to enhance patient flow and resource optimization within the hospital.

Initiatives to enhance a hospital's intelligence may include improved digital record keeping systems for patients and automated systems for inventory management. Real time operational dashboards may help optimize management of hospital resources, and reduce inefficiencies.

Integration of hospital information systems, laboratory information management systems, radiology systems and other components of the electronic medical record can also facilitate continuity of care. However, the various fragmented systems in use today present numerous challenges.

A combination of the right digital infrastructure, investment in cyber security and training, as well as good change management, are critical success factors for transformation. While many organizations are overwhelmed by the breadth and pace of change, the greatest value will come from solutions that are aligned to meet the most pressing needs of the frontline workforce and do not unduly complicate already complex workflows.

The most effective healthcare systems of the future will be judged on the integration of digital systems to improve the safety and quality of service and patient experience.

Innovation Must Be Accessible, Affordable, and Sustainable

In many developing countries, rapid improvement in care availability is limited by the cost and accessibility of advanced medical equipment and systems, and by sustainability challenges related to healthcare workforce and delivery system capacities. Innovations in medical care remain inaccessible to numerous underserved populations.



At the same time, efforts are under way in several developing countries to combine technology and medical innovation to make cost-effective improvements in healthcare. The integration of innovative, reliable, low-cost and easy-to-maintain medical equipment along the digital health continuum can play a key role in improving access to medical care for the underserved.

Sustainability is quickly becoming another critical focus area. This has led to the development of new approaches to medical waste disposal, procurement, and the management of consumables and equipment. These strategies provide the opportunity to improve an organization's environmental footprint, as well as to strengthen the operational resilience of the facility.

One must ultimately assess the true clinical value of a given medical innovation by analyzing the benefits it confers to the widest possible population. Cost, reliability, and ethical considerations must also be incorporated into a meaningful assessment of medical innovation.

The Road Ahead: Human-Centered Innovation

The intersection of new medical and surgical technologies, better data, and enhanced facilities will require the industry to concentrate on responsibility and integrity, as much as it will allow the industry to focus on breaking new frontiers in medicine.

Healthcare professionals, scientists, and engineers will also be required to work in close partnership to achieve positive outcomes.

Healthcare innovation must ultimately be grounded in the human touch. That will not change. New medical innovation, integrated with the best of technology, will propel the profession forward more than ever before.


Conclusion: Innovation That Makes a Difference

Medical innovation will not only impact how we use existing technologies, but also expand the frontiers of medicine. New diagnostic and therapeutic systems and devices will significantly improve patient outcomes and experiences.

However, what really matters when assessing the advancement of a field is its impact on people. New discoveries are useful and helpful when clinicians can make better and more adequate decisions to care for patients and strengthen healthcare systems.

What we need now is "healing innovation". As the lines between science and fiction are blurred, the most challenging yet rewarding work in healthcare is to create a future of better, more adequate and accessible, compassionate and equitable healthcare.

For the healthcare industry, the goal is to improve the systems and establish equitable, resilient and trustworthy healthcare services.





Where Diagnostics meets the future of Healthcare

Advancing Precision, Empowering Decisions, Transforming Lives

Healthcare is in the early stages of a shift where the focus is on early detection and diagnosis. The diagnostic industry will play a critical role in this evolution. Diagnostics connects the dots between the clinical suspicions of healthcare workers and the best way to care for the patient.

We are in the midst of a diagnostic revolution with a number of disruptive technologies that focus on improving health, reducing costs, and reducing the time from care to diagnosis. New innovations in laboratory and molecular diagnostics, next generation point of care testing, artificial intelligence, and other technologies are transforming the healthcare and diagnostic industry.

The goal of every diagnostic innovation should be improving patient outcomes by enabling the healthcare industry to detect, diagnose, and treat diseases in a more precise and timely manner.

The integration of various diagnostic disciplines and specializations (molecular, imaging, pathology and others) with a focus on improving health outcomes will continue to be a driver for the diagnostic revolution.

The future of diagnostics is exciting as continuous innovations in automation, digital pathology and artificial intelligence (collectively known as DILA, or Digital Integrated Laboratory Automation) along with other diagnostics focused innovations will change the landscape of healthcare.

In the meantime, diagnostics are bringing testing to the point of care, offering healthcare workers the information they need to make timely decisions at the bedside.

These innovations enable the development of diagnostic ecosystems that are quick, precise, accessible, and efficient.



Creating Advanced, Connected Laboratories

New equipment will not change diagnostics as significantly as the augmentation of workflows, QA, data management, personnel and integration. Given these challenges, laboratory automation and integration, as well as digital and wireless connectivity, are essential to improve the efficiency and integrity of diagnostic services.

New instruments must simplify the analytics of complex diagnostics, assure reproducibility, and improve compliance and data security. Innovation must align with trust, bringing value to the diagnostic ecosystem and aiding clinical decision-making.

What Lies Ahead


Achieving equitable access to affordable diagnostics, increasing the workforce and infrastructure to adequately perform diagnostics, and robustly clinically validating diagnostics remain ongoing challenges to innovation.

Finding the right balance of collaboration across diagnostic manufacturers and the aforementioned partners will help eliminate these gaps.

The diagnostics industry is forecasted to significantly transform through advancing technologies such as artificial intelligence (AI), the integration of digital health, and decentralized/point of care testing. These trends will facilitate the use of diagnostics in preventive and predictive healthcare.

The Future Begins With a Better Diagnosis

As healthcare shifts toward more proactive, preventative, personalized and patient centered models, diagnostics will be fundamental to achieving these goals.





When the **Heart and Lungs need support:** Kauvery Centre for ECMO & Advanced Life Support

At Kauvery Hospital, Vadapalani, advanced life-support technology and multidisciplinary expertise come together to support patients facing complex medical emergencies.

When the heart or lungs begin to fail, some critically ill patients may require additional support despite conventional treatment. Extracorporeal Membrane Oxygenation (ECMO) is an advanced life-support technique that temporarily supports heart and lung function by circulating blood, supplying oxygen and removing carbon dioxide. This gives medical teams valuable time to treat the underlying condition and assess recovery.

Recognising the need for specialised critical care, Kauvery Hospital, Vadapalani, has established the **Kauvery Centre for ECMO & Advanced Life Support**, bringing together specialised equipment, advanced life-support services and multidisciplinary expertise to manage complex heart, lung and multiorgan conditions.

Understanding ECMO: Support when the body needs it most

ECMO is used when the heart or lungs cannot adequately support the body despite conventional treatment. Blood passes through an external circuit, where oxygen is added and carbon dioxide removed before being returned to the body.

Different types of ECMO address specific clinical needs:

- **VV-ECMO (Veno-Venous ECMO):** Primarily supports the lungs in severe respiratory failure when oxygenation or carbon dioxide removal is inadequate.
- **VA-ECMO (Veno-Arterial ECMO):** Supports both circulation and oxygenation when the heart cannot pump sufficient blood to meet the body's needs.
- **V-AV ECMO (Hybrid ECMO):** Combines both approaches to provide comprehensive support for carefully selected patients experiencing heart and lung failure.

Selected patients may benefit from **awake ECMO**, which allows them to remain conscious without the need for continuous deep sedation or mechanical ventilation.

This approach supports early physiotherapy and rehabilitation while promoting psychosocial well-being by enabling patients to communicate with their families, eat independently and actively participate in their recovery.

The choice of ECMO depends on the patient's condition and requires continuous monitoring and careful clinical decisions by an experienced team.

Taking Critical Care beyond hospital walls

Transferring critically ill patients from hospitals without ECMO facilities can be challenging, particularly when continuous life support is required.

ECMO-supported road and air transfers help address this need. A specialised team can travel to the referring hospital, assess the patient and initiate ECMO when clinically appropriate. The patient can then be transported to Kauvery Hospital, Vadapalani, with continuous life support.

These transfers require trained personnel, specialised equipment, careful planning and coordination to maintain support throughout the journey, enabling patients to access advanced critical care.

Looking beyond the Heart and Lungs

Critically ill patients may experience complications affecting multiple organs, including the kidneys. Their care may involve specialised dialysis, fluid management, infection treatment and support for other complications.

The Kauvery Centre for ECMO & Advanced Life Support brings together ECMO specialists, cardiothoracic surgeons, cardiothoracic anaesthetists, perfusionists, cardiologists, pulmonologists, critical-care specialists, nephrologists, haematologists, infectious-disease specialists, ECMO-trained nurses, physiotherapists and other relevant clinical teams.

This multidisciplinary approach enables coordinated treatment, continuous monitoring and regular reassessment as patients' conditions and support requirements change. It helps address the wider needs of critically ill patients rather than managing complications in isolation.

Technology supported by Teamwork

While ECMO provides sophisticated life support, successful critical-care management depends on more than technology. Appropriate patient selection, timely intervention, continuous monitoring and rapid responses to changing clinical needs are equally important.

The centre combines specialised expertise with coordinated multidisciplinary care, providing appropriate life support while medical teams treat the underlying illness and evaluate the patient's response.

Expanding the Possibilities of Critical Care


For critically ill patients and their families, medical emergencies often involve complex decisions and uncertain outcomes. ECMO offers an additional treatment pathway for selected patients when conventional measures are insufficient. Through the **Kauvery Centre for ECMO & Advanced Life Support**, Kauvery Hospital, Vadapalani, is strengthening its capabilities in advanced heart and lung support, ECMO-assisted patient transfers and multiorgan critical care. By bringing together specialised expertise, advanced technology and timely clinical decisions, the centre aims to provide critically ill patients with appropriate support while medical teams work towards the best possible outcome.

Article attributed to:



Dr. K. Madhan Kumar,
Director – ECMO & VAD | Senior Consultant – Cardiothoracic & Transplant Surgeon, Kauvery Hospital, Vadapalani





Park Hospital Marks Groundbreaking of Rs. 200 Crore, 550-Bed Multi-Super-Speciality Hospital in Prayagraj

New facility strengthens Park Medi World's expansion in Uttar Pradesh and reinforces its growing presence across North India

Park Hospital, part of Park Medi World Limited, marked the groundbreaking ceremony for its upcoming 550-bed multi-super-speciality hospital in Prayagraj, Uttar Pradesh. With an investment of approximately Rs. 200 crore, the project represents a significant milestone in the Group's expansion plans and its efforts to strengthen healthcare infrastructure in the region.



Park Hospital Marks Groundbreaking of Rs. 200 Crore, 550-Bed Multi-Super-Speciality Hospital in Prayagraj

The hospital is being developed under a public-private partnership (PPP) with the Prayagraj Municipal Corporation.

The project is expected to expand access to organised, multi-speciality healthcare for residents of Prayagraj and neighbouring areas.

Park Hospital
Advanced Super Speciality

The facility is targeted for completion within two years from the appointed date under the concession agreement. The groundbreaking marks the next stage of a project for which Park Medi World received the PPP mandate in August 2026.

The development forms part of the Group's broader strategy to expand its hospital network across emerging healthcare markets and strengthen its presence beyond established metropolitan centres.

Park Medi World currently operates a network of 17 hospitals with a combined capacity of approximately 4,290 beds. The Group is working towards expanding its network capacity to approximately 6,660 beds by December 2028 through a combination of new hospital developments, acquisitions and capacity additions at existing facilities.

The Prayagraj project builds on the Group's growing presence in Uttar Pradesh, where it already operates a 360-bed hospital in Agra and will soon be commissioning two new hospitals in Kanpur and Gorakhpur under the O&M model. Together, these projects are expected to strengthen Park's healthcare footprint across the state and expand its ability to serve patients across a wider regional catchment.

The Group also has an established presence in Punjab through facilities including Park Hospital Bathinda, Park Hospital Patiala and Park Hospital Mohali. Its wider network spans 15 cities across 6 states in North India, supported by investments in hospital infrastructure, clinical capabilities and patient services.

Commenting on the development, **Dr. Ankit Gupta, Managing Director, Park Medi World Limited**, said, *"The groundbreaking of our Prayagraj hospital marks an important milestone in our expansion journey. As we work towards increasing our network capacity to approximately 6,600 beds by December 2028, our focus remains on strengthening our presence across North India and expanding access to healthcare in emerging markets. Prayagraj is an important addition to our growth plans, reflecting our commitment to developing healthcare infrastructure that responds to the needs of the communities we serve."*

Through its planned investments and capacity additions, Park Medi World aims to strengthen its regional presence and expand access to multi-speciality healthcare across established and emerging markets.

About Park Medi World Limited

Park Group is North India's 2nd largest hospital chain, currently operating 17 hospitals with a combined capacity of ~4,300 beds as on date. Together with this proposed 550-bed PPP facility at Prayagraj, the Group is in the process of integrating 6 additional hospitals and expanding capacity at 3 existing units. These are in various stages of execution and will add ~2,300 beds to our network. With these, Park Group's total capacity is expected to reach ~6,600 beds, underscoring its commitment to leadership and growth in healthcare delivery.



The Group has established a strong presence across 15 key cities including Delhi, Gurgaon, Faridabad, Panipat, Karnal, Sonipat, Ambala, Mohali, Patiala, Bathinda, Behror, Jaipur, Agra, Panchkula and Rudrapur, and is expanding into Zirakpur (Punjab), Kanpur, Gorakhpur, Prayagraj (Uttar Pradesh) and Rohtak (Haryana). Built on a commitment to accessible, high-quality healthcare, Park Group offers a comprehensive range of clinical services—spanning super-specialities such as cardiology, neurology, oncology, orthopaedics, gastroenterology, critical care, nephrology, organ transplants, and women & child health. Each facility is equipped with modern medical infrastructure, advanced diagnostics, 24×7 emergency support, and multi-disciplinary teams delivering evidence-based care. Through continuous expansion and strategic investments, Park Group is strengthening its mission to build a dependable, technology-enabled healthcare ecosystem that serves both metropolitan and regional communities across North India.

Ramaiah Memorial Hospital Brings 700+ Citizens Together to Put Heart Health in Motion

On **World Heart Day**, Ramaiah Memorial Hospital (RMH) brought together more than 800 citizens at its **Community Fitness Festival**, themed "**Don't Miss A Beat,**" blending physical activity, cardiac health awareness, and hands-on CPR training to inspire people to make heart health part of their everyday routine.



Film Actresses Kavya Shetty, Shanvi Srivastava & Dr. Madan S Gaekwad - COO, Ramaiah Memorial Hospital and others participated in the heart care awareness programme organised by RMH

The morning event at Dwaraka Hall, Ramaiah Campus, was flagged off by **Dr. Madan S. Gaekwad, Chief Operating Officer (COO), Ramaiah Memorial Hospital.** Participants took part in Aerobics, Zumba, and Tai Chi sessions, stressing on the role of regular exercise in maintaining cardiovascular health.

RAMAIAH
Memorial Hospital

The event was also graced by Kannada and Telugu film actresses **Shanvi Srivastava and Kavya Shetty**, who joined the initiative and urged citizens to prioritise fitness and heart health in their daily lives.

Moving beyond awareness, RMH's medical experts led focused health sessions on cardiovascular wellness and conducted hands-on CPR training, equipping participants with the skills to respond confidently during a cardiac emergency. The festival concluded with a specially curated healthy-heart breakfast, reinforcing how everyday choices support long-term heart health.

Through the initiative, RMH brought preventive cardiac care into a community setting — encouraging citizens to stay active, understand their heart health, and be prepared to act when it matters most.

About Ramaiah Memorial Hospital

Ramaiah Memorial Hospital (RMH), established in 2004, is a 500 bed, JCI-, NABH- and NABL-certified multi-disciplinary super specialty quaternary care hospital in Bengaluru, India. RMH received the Joint Commission International (JCI) Gold Seal of Approval in June 2025. The Gold Seal of Approval is a symbol of a healthcare organization's commitment to meeting international standards of patient care and safety, demonstrating excellence in clinical quality, patient safety, and outcomes. In June 2025, RMH was also certified by the American Heart Association (AHA) as a Comprehensive Chest Pain Center and by the American Stroke Association (ASA) as a Comprehensive Stroke Center. The recent FACT (Foundation for the Accreditation of Cellular Therapy) accreditation of our Bone Marrow Unit and stem cell laboratory reflects our adherence to rigorous, peer-reviewed standards, ensuring the highest quality of patient care across the entire stem cell process—from collection and processing to administration and long-term follow-up.

Over the years, the hospital has touched the lives of over 5 million patients and performed more than two lakh surgeries. Its transplant milestones are close to 600 renal transplants, over 50 heart transplants, more than 210 bone marrow transplants, and liver transplant services initiated in 2025.

Ramaiah Memorial Hospital is affiliated with Mount Sinai International, New York from June 2024, marking a transformative collaboration focused on elevating healthcare through excellence in clinical care, quality, research, innovation, and technology.

Our Centers of Excellence, such as the Ramaiah Institute of Cardiac Sciences, Ramaiah Institute of Oncosciences, Ramaiah Institute of Nephro-Uro Sciences, Ramaiah Institute of Neurosciences, and the Ramaiah Institute of Gastro-intestinal Sciences are delivering comprehensive healthcare services under respective specialties along with other super-specialties.

RMH has received recognition from Newsweek as one of the World's best hospitals in 2025. The ranking is based on hospital recommendations from peers, hospital quality metrics, patient experience, and PROMs implementation survey

Puducherry Nephrologist Dr. N. Murugesan Introduces 'Blue Nephrology', a Prevention-First Approach to Kidney Health

Puducherry-based nephrologist and Founder-Chairman of **East Coast Hospitals**, **Dr. N. Murugesan**, has introduced "**Blue Nephrology**", a prevention-focused approach that seeks to identify and address metabolic and lifestyle risks affecting kidney health before they develop into serious disease.



Dr. N. Murugesan

The concept forms part of the Blue India Movement, inspired by the world's Blue Zones and their experience of healthier ageing. It proposes looking beyond the treatment of kidney disease to earlier risk factors such as insulin resistance, diabetes, hypertension and excessive sodium intake.

The Dr. Blue India Foundation, established by Dr. Murugesan in Puducherry in 2025, is translating the approach into community-level action through a Rs 30-crore philanthropic initiative to provide one lakh free insulin tests. The programme aims to identify metabolic risks among people who may not yet have obvious symptoms.

With more than five decades of medical service and over four decades in nephrology, Dr. Murugesan has spent much of his career treating kidney disease. His current focus is on moving kidney care further upstream—from treating disease after it develops to identifying risks earlier.

We have traditionally asked how to treat kidney disease. The more important question is whether we can protect kidney health before disease develops," said **Dr. Murugesan**.

For more than two decades, Dr. Murugesan has also worked on the health effects associated with excessive sodium intake and approaches to reducing sodium exposure. He sees kidney health as an important window into wider metabolic and cardiovascular health.

The larger objective is to shift the focus from treating disease after it appears to identifying and addressing health risks much earlier.

drblueindia.com
www.eastcoasthospitals.com

Dr. N. Murugesan

Dr. N. Murugesan is a nephrologist from Puducherry who has spent nearly four decades working in nephrology, kidney transplantation and tertiary healthcare. His career has combined clinical practice with institution building and, more recently, public-health initiatives aimed at early detection and prevention of chronic diseases **resulting in overall healthy longevity.**

Dr. Murugesan completed his MBBS in 1977, followed by his MD in 1981, and subsequently became the first in Soth India to get a DNB in Nephrology in 1987. He trained in nephrology under Padma Vibhushan Dr. M. K. Mani in Chennai.

"
Dräger
Technology for Life
Beyond Maintenance
—
Service That Supports Care
LEARN MORE



Apollo Knowledge and BITS Pilani Partner to Advance Healthcare Research and Build India's Healthcare Technology Workforce

Collaboration will cover joint research, Work Integrated Learning programmes for healthcare professionals, and specialised allied health and healthcare technology programmes

Apollo Knowledge and the Birla Institute of Technology and Science, Pilani (BITS Pilani) have come together to work on healthcare research, education and workforce development. The two signed a Memorandum of Understanding today in the presence of Dr. Prathap C. Reddy, Founder-Chairman, Apollo Hospitals Group, Dr. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Enterprise Limited, and Prof. V. Ramgopal Rao, Group Vice-Chancellor, BITS Pilani.



Collaboration will cover joint research, Work Integrated Learning, and specialised healthcare

The collaboration brings together the clinical environment of the Apollo network and BITS Pilani's strengths in engineering, technology and data science. Clinicians and BITS Pilani researchers will explore joint research on clinical and healthcare problems, with specific areas to be identified as the collaboration develops.

The two institutions will collaborate to develop Work Integrated Learning programmes for healthcare professionals.

These programmes allow doctors, nurses, allied health professionals and healthcare managers to earn a qualification while continuing in their jobs. Potential areas include healthcare logistics and supply chain, pharmacy, and hospital finance, with the curriculum built around the work these professionals actually do.

The partners will also explore technology learning for students, built around the role each student is training for. This would extend to learners at The Apollo University, at the medical and nursing colleges in the Apollo network, and at Apollo Healthcare Academy's partner institutions.

Specialised programmes in allied health and healthcare technology are a further area the two institutions will explore, combining BITS Pilani's competency centres with clinical training in Apollo hospitals.

Dr. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Group, said, *"Healthcare is entering an extraordinary era, where technology is opening new possibilities and widening the horizons of diagnosis, treatment and care. Yet the future of healthcare will be shaped not by technology alone, but by our ability to bring high tech and high touch together, combining innovation with the human connection that lies at the heart of healing. This landmark partnership brings together two pioneering institutions, Apollo Hospitals and BITS Pilani, each with a legacy of transforming its field and a shared belief in the power of knowledge to shape the future. Together, we can enable healthcare professionals to learn while they continue to care, build capabilities for a rapidly changing world, and advance research rooted in the challenges clinicians encounter every day. In doing so, we hope to nurture a generation of healthcare professionals ready not only for the future of healthcare, but ready to shape it."*

Prof. V. Ramgopal Rao, Group Vice-Chancellor, BITS Pilani, said, *"Healthcare is one of the areas where good engineering makes a direct difference to people's lives. The collaboration creates opportunities to work with Apollo's clinical ecosystem and with a large base of healthcare professionals and students. We bring the technology, data science and a proven model of teaching people who are already working. We expect this collaboration to produce both research and trained professionals."*

About Apollo Knowledge

Apollo Knowledge is a higher education, skilling and workforce development group backed by the promoters of Apollo Hospitals, working across medicine, nursing, allied health, technology and management. Its institutions include The Apollo University, Apollo Institute of Medical Science and Research, Apollo Nursing Colleges, Apollo Healthcare Academy, Medvarsity and Global Workforce Development.

More than 10,000 students are on campus today, undergoing clinical training in the hospitals. More than 5,000 healthcare professionals have been placed in roles in India and abroad, including over 400 radiographers who joined the National Health Service in the United Kingdom in the last three years.

About BITS Pilani

The Birla Institute of Technology and Science, Pilani (BITS Pilani) is a leading private deemed-to-be university in India, founded in 1964 under the patronage of the Birla family.

It was among the first six institutions in India to be declared an Institution of Eminence by the Government of India. BITS Pilani operates campuses at Pilani, Goa, Hyderabad, Mumbai and Dubai.

Its Work Integrated Learning Programmes division has offered degree programmes for working professionals since 1979. More than 1,36,000 professionals have graduated through these programmes, and over 50,000 are currently enrolled across India and more than 32 countries. Over 350 companies work with BITS Pilani for workforce development.



Delhi's LNJP Hospital Adds Advanced 3-Tesla MRI and 256-Slice CT Scanner in ₹40 Crore Upgrade



Delhi's Lok Nayak Hospital (LNJP), one of the capital's major government healthcare facilities, has upgraded its diagnostic infrastructure with the installation of a 3-Tesla MRI scanner and a dual-source 256-slice CT scanner. The equipment was inaugurated by Delhi Chief Minister Rekha Gupta and Health Minister Pankaj Kumar Singh. The two systems cost approximately ₹40 crore and were funded through Indian Oil Corporation Limited's corporate social responsibility programme.


The upgrade addresses a long-standing shortage of advanced diagnostic imaging capacity at the hospital. Before the installation, the facility reportedly had only one functional MRI machine and one CT scanner, contributing to extended waiting times for patients requiring scans.

The new 3-Tesla MRI system provides high-field magnetic resonance imaging for detailed assessment of soft tissues, neurological conditions, musculoskeletal disorders and other clinical indications. The dual-source 256-slice CT scanner is designed to acquire detailed cross-sectional images rapidly, supporting applications that include cardiovascular and emergency imaging.

LNJP Hospital handles approximately 5,000 outpatient visits daily, making diagnostic throughput an important factor in its clinical operations. The hospital expects the new equipment to double its previous MRI and CT scanning capacity, helping more patients access investigations in a timely manner.

The installation also highlights the importance of public-private collaboration in expanding government hospital infrastructure. CSR-supported medical equipment programmes can help public hospitals acquire advanced technologies without relying entirely on their routine capital budgets.

For India's hospital sector, the project demonstrates how investments in imaging infrastructure can improve diagnostic capacity and support clinical decision-making. Actual reductions in waiting times will depend on staffing, maintenance, operating schedules and the number of scans that can be performed each day.



MEDICAL FAIR INDIA

www.medicalfair-india.com

India's No.1 Trade Fair
For Hospitals, Health Centres and Clinics

Connect, Witness & Lead the Future of Healthcare

13-15 March 2027

Hall 4 & 5, Bharat Mandapam
(Pragati Maidan) New Delhi

20-22 August 2027

Hall 2 & 3, Bombay Exhibition Center
Goregaon (E), Mumbai



Special Features

AiMeD - Make In India Pavilion

Clin Lab / IVD Pavilion & Conference

Future for Health Digital Health Start-up Pavilion & Conference

Introducing new segment
Rehabilitation Pavilion

Dedicated Platform for
Raw Materials, Components, Machinery, Services & MedTech Manufacturing Solutions
MMI Pavilion & Conference

International Conferences

MT India Healthcare Awards

Show Highlights 2027

15,500 m²
Exhibit Area

500+
Exhibiting Brands from 14+ Countries

18,000+
Visitors from 30+ Countries

450+
Delegates

4
International Conferences

For more information, please contact: Adarsh Verma, Director - Projects | VermaA@md-india.com | 91-124-4544 507

An initiative by

MEDICARE ASIA

Supported by

Media Partner

Microbioz India

Messe Düsseldorf India



Beyond the Tube: Engineering Better Respiratory Circuits **Through Silicone Expertise**

An OEM-focused perspective on materials, manufacturing, integration and reusable respiratory solutions.

In respiratory and anaesthesia equipment, an understanding of breathing circuits can go a long way. However, from a manufacturing perspective, a breathing circuit is made of a combination of several components that need to be assembled in a reliable manner to function under defined operating conditions. The choice of silicone, the design of the tube, the method of joining components and the choice of connectors are some factors that influence the final product.

Over the years, one thing has been apparent to us, the development of a reliable respiratory circuit is more than manufacturing a tube. This is because manufacturing a reliable respiratory circuit is also dependent on the understanding of the application, the right choice of material, and the selection of the right manufacturing process for the components.

At Ami Polymer, the knowledge and experience we have in processing silicone has given us the ability to understand respiratory products as integrated systems as opposed to a collection of individual components. We work in conjunction with OEMs to manufacture respiratory components (breathing tubes) and other respiratory and anaesthesia products based on the requirements of the OEMs.

Silicone: Understanding the Material Beyond its Basic Properties

When selecting a material for breathing tubes, various factors must be taken into account together with the inner diameter and wall thickness of the tube. The geometry of the tube and the degree of flexibility required must also be taken into account.

The tube must allow the circuit to be arranged in various positions without causing kinking or excessive deformation that would restrict the tube's passage.

Also, the level of transparency of the tubing is an important consideration. The type of formulation and process used affect the level of transparency a product can achieve.

We select a material based on the actual requirement. We understand the requirement and the purpose of the end product to be supplied; we can then evaluate the product in question against the OEM's criteria.

Extrusion and Moulding: Choosing the Right Process

One of the major considerations in manufacturing components of a respiratory circuit is determining the best production process.

In the case of continuous tubing, extrusion offers a relatively efficient process to produce tubing to a specified size (cross-sectional dimensions) over a wide range of lengths. It can also be used to manufacture tubing with an inner diameter and outer diameter that remains uniform and constant over its length. Moulding serves a different purpose. It is used for components that require complex shapes, connection features and/or integrated designs. In the fabrication of respiratory circuits, both manufacturing strategies (extrusion for tubing and moulding for functional components) can be deployed in conjunction. The critical aspect is to select the process that satisfies the design requirement, as opposed to producing all the components using the same method.

Overmoulded Cuffs: Rethinking Component Assembly

Overmoulding can also improve component assembly. For example, rather than separately manufacturing a cuff and using adhesive to attach it to a tube, overmoulding can be used to manufacture the cuff and integrate it to the tube. This can simplify the assembly and eliminate the need for a separate adhesive bonding.

Overmoulding requires careful consideration of the design and the integration of various components (such as a tube and a cuff) during the product development. Although this simplifies the assembly and reduces costs, it must be evaluated to determine if the final product meets the performance requirement for integrity and leakage.

As manufacturing decisions can affect the design of a product, we believe these decisions should be made early in the OEM design process.

Connectors and Water Traps: Small Components, Big Functions

While the role of the tube in a respiratory circuit is critical, the role of the connectors and moisture-management components is equally important. They all must work in conjunction to create a complete assembly that functions effectively.

Various configurations of connectors are available to help construct the required circuit pathways and routing. Their shapes, dimensions, and connection interfaces must be compatible with the tubing and other mating components.

At Ami Polymer, we manufacture both polycarbonate and polysulfone Y connectors and elbow connectors, subject to product specification. Consideration for material selection should be based on mechanical requirements, anticipated temperature exposure, and chemical and clean/sterilize compatibility.

Reusable Silicone Breathing Circuits: Analyzing the Entire Service Life

Disposable breathing circuits offer convenience, since they are meant for single use and, therefore, do not require reprocessing between uses. However, they are single use and create waste from repeated procurement and disposal.

We provide reusable silicone breathing circuit solutions for OEM evaluation for product designs and intended uses that allow for reusability in combination with validated reprocessing.

Durable silicone does not, in itself, justify consideration for reusability. It is more important to analyze a product over its entire service life.

A reusable product, designed for multiple use, can help reduce the number of complete assemblies that must be replaced. It can also help reduce overall costs of ownership, especially in facilities where reprocessing is undertaken.

Like any medical device, the benefits associated with a reusable circuit cannot be generalized to other hospitals or applications. Total costs consist of cleaning, disinfection or sterilization, labor, inspection, storage, and eventual replacement. The environmental impact is the result of the resources consumed during reprocessing and the actual service life of the device.

Therefore, reusable circuits must be designed and validated to withstand their intended conditions of reuse. Compatibility of the materials used, effectiveness of cleaning, microbial safety, performance and functions after reprocessing, and replacement are all considerations.

In our opinion, reusable and disposable products should be considered based on the requirements of the application. The intent is to provide OEMs alternative design approaches, while ensuring safety and quality are maintained, and validated performance is integral to the decision.

Complete Respiratory and Anaesthesia Circuits

While working with OEM manufacturers, we understand the product development process is usually to integrate several components or subassemblies versus developing a standalone component. These components can include tubing size, cuff interfaces, connectors, patient interfaces and heating systems.

We have developed products for various respiratory and anesthesia applications, including:

1. Continuous length ventilator breathing tubes made from silicone.
2. Tubing with overmoulded cuffs.
3. Water traps for respiratory circuits.
4. Y and elbow connectors in Poly-sulfone and Poly-carbonate.
5. Reusable Silicone breathing tubes for validated reusable applications.
6. Anaesthesia masks for their desired patient interfaces.
7. Respiratory circuits for temperature management of the gas pathway.
8. Catheter mounts for respiratory circuits.

Heated-wire circuits incorporate design considerations including tubing, the heating system, humidification, and electrical safety.

There are also interface and performance considerations for anesthesia masks and catheter mounts. Each component must be developed and assessed for its intended function.

Ami Polymer supporting multiple product categories allows them to partner with OEMs for broader requirements for respiratory circuits.

This provides an opportunity for manufacturers to engage with Ami Polymer for material selection, component interfaces, and assess the potential for customization and manufacturing of the product.

Quality Must Be Built Into the Complete Product

In medical device manufacturing, a process or material advantage is only meaningful when the final product meets its defined requirements.

The performance evaluation of respiratory tubing and components may include inspection for correct dimensions, transparency evaluation, kink resistance, and assessments for integrity and leaks.



The retention of connectors and flow must also be evaluated. When a component is intended for repeated use, assessment of its performance following a defined cycle of reprocessing must also be done.

The clinical application of the product must also be considered along with biologic safety, and other regulatory concerns. The finish assembly must be assessed for component compatibility.

We believe early involvement of the OEM is essential to define the requirements discussed above prior to the finalization of the tooling and manufacturing process of the product.

Identifying the intended use of the product helps define the constraints of manufacturing, opportunities for component integration and the tests needed to validate the product for its intended use.

From Component Supply to Engineering Collaboration

The respiratory industry is continuously changing and as a supplier, you need to understand both material behavior and manufacturing process. A component like tube, cuff or connector cannot be assessed in isolation when it is part of a complete respiratory system.


At Ami Polymer, when we undertake the manufacture of respiratory components, we consider the entire system. Whether the requirement is a customized extruded tubing, overmoulded cuff, water trap, connector, breathing circuit or an anesthesia mask, we evaluate the requirement based on the end use of the customer.

Our interest is to help the OEM customer develop a product that is application specific and which can be manufactured consistently and validated for the end use.

Ultimately, good respiratory circuit design comes from getting the details right: the material, the dimensions, the interfaces, the manufacturing method and the requirements of the complete assembly.

At Ami Polymer, we believe that our role extends beyond supplying silicone components. It is about working with OEM manufacturers to develop respiratory and anaesthesia solutions in which material expertise, manufacturing capability and application requirements come together.

Authored By:
Vishal Nair
Assistant Manager | Healthcare Division
Email: medical@amipolymer.com
Website: www.amipolymer.com



Park Group Expands into Uttarakhand with 330-Bed The Medicity Hospital in Rudrapur



Park Group of Hospitals has expanded its presence in North India with the launch of The Medicity Hospital, a 330-bed multispeciality facility in Rudrapur, Uttarakhand. The opening marks the group's entry into the state and expands its operational presence across six states in North India.

The hospital is positioned as a major regional healthcare destination for Rudrapur and the wider Kumaon region. Its opening is intended to improve access to organised specialist care for patients who might otherwise need to travel to larger cities for certain treatments.


The new facility adds inpatient capacity and expands the availability of multispeciality services in an area where demand for advanced healthcare is growing. Hospitals of this scale can provide a platform for coordinated medical and surgical services, supported by diagnostic and critical-care infrastructure.

For Park Medi World, the launch is part of a wider expansion strategy focused on strengthening its hospital network and developing regional centres of excellence. Increasing the number of operational beds can help the group serve more patients, although utilisation depends on local demand, clinical capabilities and staffing.

The expansion also reflects a broader trend in India's hospital sector: private healthcare groups are increasingly investing in smaller cities and regional markets rather than concentrating exclusively on major metropolitan areas.

Park Hospital
Advanced Super Speciality

The hospital's long-term contribution will depend on the range of services available, specialist recruitment, patient access and the quality of clinical operations. The launch is an operational milestone for Park Group and a significant addition to Uttarakhand's private hospital infrastructure.



IHH Healthcare Plans to Increase Fortis Healthcare Stake to 51% and Expand Capacity to 10,000 Beds




Malaysia-based IHH Healthcare has announced plans to increase its shareholding in Fortis Healthcare to 51% over the next three to five years and expand the combined hospital platform's capacity to approximately 10,000 beds by 2031. The announcement signals a long-term commitment to the Indian hospital market.

The proposed expansion would strengthen IHH's position in India's private healthcare sector and support the development of a larger hospital network. Fortis Healthcare is an established Indian provider with multispeciality hospitals and diagnostic services.

IHH has also indicated plans to further integrate its Fortis and Gleneagles platforms. Greater operational coordination could create opportunities to share clinical expertise, strengthen specialist services and improve the utilisation of hospital infrastructure across the network.

The capacity target reflects the scale of investment required to respond to India's growing demand for tertiary and quaternary healthcare.

These services include complex cardiac procedures, oncology, organ transplantation and other specialised treatments that require advanced facilities and experienced clinical teams.



The announcement comes amid increasing interest from international investors in Indian healthcare infrastructure. Hospital operators are competing to expand their geographic presence, recruit specialists and develop centres capable of managing more complex cases. The 10,000-bed figure is a future target rather than current operational capacity. Achieving it will depend on capital expenditure, new hospital developments, acquisitions or expansions, regulatory requirements and the successful integration of existing operations.

Nagpur's ₹187.7 Crore Wathoda Super-Speciality Hospital Nears Completion with 300 Beds Planned



Construction of the 300-bed super-speciality hospital at Wathoda, Nagpur, is nearing completion, marking a major step towards adding hospital capacity in Maharashtra. The project, being executed by the Nagpur Improvement Trust (NIT), carries an estimated cost of ₹187.7 crore.

Civil construction is largely complete, with work focused on finishing the building. The next major phase involves installing medical equipment and preparing the facility for its eventual clinical operations.

The planned 300-bed capacity is intended to strengthen the city's healthcare infrastructure and provide additional scope for specialist inpatient services.

Super-speciality hospitals typically require integrated diagnostic facilities, operating theatres, intensive-care units and other specialised clinical infrastructure.

The transition from construction to commissioning is a critical stage in hospital development.

Equipment installation must be followed by testing, safety checks, operational preparation and the recruitment of appropriate clinical and support personnel. For Nagpur, the project represents a substantial public healthcare infrastructure investment. Additional hospital capacity can help address regional demand, although the actual benefit will depend on the services offered, staffing levels, patient access and the date the facility begins accepting patients.

As of 17 October 2026, the hospital was reported to be nearing completion, but a confirmed opening date had not been announced in the cited report. The facility should therefore be described as an upcoming hospital rather than an operational one.





AIG Hospitals Attracts Interest from Global Investors in Potential ₹2,500 Crore Stake Deal



Hyderabad-based AIG Hospitals has emerged as a major focus of international healthcare investment, with Novo Holdings, Singapore's sovereign wealth fund GIC and Abu Dhabi-based Axight reportedly in advanced discussions with EQT to invest ₹2,000–2,500 crore in the multispeciality hospital group.

The proposed transaction could value AIG Hospitals at approximately ₹24,000 crore.

The discussions reportedly involve the hospital's founders considering the sale of a 10–12% stake. If completed on the reported terms, the transaction would represent a significant investment in one of India's prominent specialist-led hospital networks.

AIG Hospitals, formally known as the Asian Institute of Gastroenterology, has built its reputation in gastroenterology, hepatology, digestive diseases and advanced endoscopy. Its clinical operations also encompass other

specialities, supporting its position as a tertiary-care provider.

The reported investor interest reflects the growing appetite of global institutional investors for Indian hospital businesses. Established hospital chains offer opportunities to expand clinical capacity, develop new facilities and increase access to specialised treatments in a market experiencing rising demand for organised healthcare. For EQT and potential incoming investors, a transaction could also create opportunities to support AIG's future growth, strengthen its infrastructure and enhance its regional presence.

However, the precise investment structure, governance arrangements and use of funds would depend on the final agreements.

Deal status: As of 15 October 2026, the investment was reported to be under advanced discussion, not a completed transaction. The reported valuation and investment amount should therefore be treated as indicative until confirmed by the parties.

Advent International Announces ₹3,150 Crore Investment in Yatharth Hospitals

Global private equity investor Advent International has announced a ₹3,150 crore investment in Yatharth Hospital & Trauma Care Services Limited for a significant minority stake. The investment is one of the notable private equity transactions in India's hospital sector in 2026 and is intended to support Yatharth's next phase of expansion. Yatharth Hospitals has developed a network of multispeciality facilities serving patients across Delhi-NCR and other parts of North India. Its clinical services span areas such as cardiology, neurology, orthopaedics, oncology, critical care and other specialist treatments.



The proposed capital investment offers the hospital group an opportunity to accelerate capacity expansion, strengthen its existing facilities and pursue additional growth opportunities. Private equity funding can also support investments in medical technology, clinical infrastructure, specialist recruitment and operational capabilities.

The transaction reflects a broader trend in which global investment firms are backing established Indian hospital chains that have opportunities to expand into new markets. Growing demand for complex medical procedures, an expanding insured population and the development of organised healthcare in smaller cities are contributing to investor interest.

For Yatharth, access to institutional capital could support a more ambitious growth strategy while providing financial flexibility for new projects and acquisitions. The investment also places the company within a competitive landscape where hospital groups are seeking scale, greater geographic coverage and stronger clinical capabilities.

The precise ownership structure, investment conditions and deployment schedule should be verified against the final transaction disclosures. The announcement is particularly significant for hospital executives and investors tracking consolidation and capital flows into India's healthcare delivery sector.



KKR Acquires Medicover India's Hospital Business in Major Healthcare Transaction




Global investment firm KKR announced the acquisition of Medicover AB's Indian hospital business, marking a major transaction in India's private healthcare industry. The deal was reported in August 2026, with industry sources estimating the hospital chain's valuation at approximately ₹10,000 crore.

Medicover's Indian operations comprise a network of 24 hospitals, providing KKR with an established healthcare platform and an opportunity to participate in the long-term growth of India's hospital market.

The acquisition aligns with KKR's strategy of investing in healthcare businesses that can benefit from operational development, infrastructure investment and expanding demand for specialised medical services. The firm has experience investing in healthcare platforms across several markets. Industry reports have also indicated that KKR may consider an additional ₹3,000–4,000 crore investment to support the business's expansion. This potential capital commitment would be separate from the reported acquisition valuation and should not be treated as a confirmed investment unless formally announced.

For Medicover's Indian operations, the change in ownership could create opportunities to expand hospital capacity, strengthen clinical services and pursue additional markets. The impact on employees, patients and existing operations will depend on the final integration strategy and operational priorities.

The transaction demonstrates the continuing importance of private equity in the development of India's hospital infrastructure. Investors are increasingly looking at established hospital networks as platforms for long-term growth rather than treating individual facilities as standalone investments.



Manipal Hospitals Expands Bengaluru Presence with ₹130 Crore Kinder Women's Hospital Acquisition



Manipal Health Enterprises, which operates the Manipal Hospitals network, signed an agreement to acquire the operations and assets of the 100-bed Kinder Women's Hospital in Bengaluru for ₹130 crore. The acquisition strengthens Manipal's presence in the Whitefield area, one of Bengaluru's important healthcare markets.

manipalhospitals
LIFE'S ON

Kinder Women's Hospital, located in Doddanekundi, provides specialised women's healthcare services. Its addition gives Manipal an opportunity to expand its reach in maternity care, gynaecology and related specialist services within an established hospital network.

The transaction is structured as an acquisition of the hospital's business and assets rather than a purchase of shares in its operating company. The agreement was signed with Kindorama Healthcare Private Limited, and completion was expected within 90 days, subject to customary and statutory approvals.

The acquisition is consistent with Manipal's approach of combining selective acquisitions with organic hospital development. Existing facilities can provide an established patient base, trained staff and operational infrastructure, potentially allowing a hospital group to expand more quickly than building a new facility from the ground up.

For Manipal, the purchase strengthens its existing Bengaluru cluster and provides an opportunity to integrate specialised women's healthcare with its broader clinical network. Greater coordination may also create referral opportunities between maternity services and other medical specialities.

The transaction illustrates how hospital groups are using targeted acquisitions to strengthen their presence in specific urban markets. The ultimate business benefits will depend on integration, service quality, patient volumes and the efficient use of existing capacity.

Manipal Hospitals Plans to Add 2,426 Beds by 2030, with Greenfield Projects Leading Expansion

Manipal Hospitals plans to add approximately 2,426 beds by 2030, with around 80% of the planned capacity expected to come from greenfield developments, according to reporting on the company's annual report and expansion strategy. The plan signals a shift towards building new facilities alongside its established acquisition-led growth model.

The proposed expansion comprises approximately 1,943 greenfield beds and 483 beds through brownfield projects.





Greenfield development involves constructing new hospitals, while brownfield expansion adds capacity to existing facilities.

Manipal's planned growth focuses on markets where it already has a presence, including Karnataka, Maharashtra, Goa and eastern India. Concentrating on established regions may allow the group to build on existing brand recognition, clinical networks and operational capabilities.

The company's acquisition strategy has significantly increased its scale over recent years. Its acquisitions have included Columbia Asia, Vikram Hospitals, AMRI, Medica Synergie and Sahyadri Hospitals. The Sahyadri acquisition, in particular, strengthened its position in Maharashtra.

manipalhospitals
LIFE'S ON

The expansion strategy comes with financial and operational challenges. New hospitals require substantial capital expenditure, and recently commissioned facilities generally take time to achieve optimal occupancy. Staffing, specialist recruitment, equipment procurement and patient acquisition are therefore essential to the success of new projects.

Manipal's plan reflects a wider shift in the Indian hospital industry: major groups are balancing acquisitions with new construction to increase capacity over the long term. The stated 2,426-bed pipeline is a target, and actual additions will depend on project execution, approvals and market conditions.

India's Hospital Chains Prepare to Invest ₹40,000 Crore in More Than 34,000 Additional Beds



India's major private hospital chains are preparing for a substantial expansion cycle, with 18 leading groups planning approximately ₹40,000 crore in investment to add more than 34,000 beds by FY2030, according to an industry analysis published in September 2026.

The figures highlight the scale of capital being directed towards healthcare delivery infrastructure.



The expansion plans involve established healthcare brands including Apollo Hospitals, Max Healthcare, Fortis Healthcare, Medanta, KIMS and Manipal Hospitals. Their strategies combine greenfield hospitals, additions to existing facilities, acquisitions and operating partnerships.

Demand for specialised procedures is a major factor supporting investment. Oncology, cardiology, neurosciences and organ transplantation are becoming increasingly important components of hospital business models, while higher patient volumes and greater demand for organised healthcare are supporting revenue growth.

However, adding beds does not automatically translate into stronger profitability. New hospitals often incur substantial pre-opening costs and initially operate at lower occupancy. Hospital groups must therefore balance capital deployment with the time needed to establish clinical teams, attract patients and build referral networks.

The expansion is also raising questions about affordability and geographic distribution. Private investment can add capacity and advanced medical services, but the benefits will depend on where facilities are located, the pricing of services and the availability of insurance or public healthcare support.

For healthcare investors and hospital operators, the coming years are likely to be shaped by the balance between scale, service quality, financial returns and access to care. The planned investment represents a significant opportunity for medical-device manufacturers, diagnostic suppliers, hospital furniture companies and healthcare technology providers serving the expanding hospital ecosystem

PRESENTING THE 11TH
EDITION OF **MEDIA PLANNER**
— AVAILABLE NOW



For copies: support@microbiozindia.com



Leica Biosystems Launches Laser Cassette Printer for Histology Labs



The system prints barcodes and 2D codes in up to 2.5 seconds per cassette and uses ink-free laser printing to support specimen traceability and reduce maintenance.

Leica Biosystems announced the global launch of the HistoCore Lightening C Laser Cassette Printer. The platform is designed to standardize histology workflows, enhance specimen traceability, and speed sample processing in pathology laboratories facing rising test volumes and staffing shortages. According to the company, the system delivers specimen identification at the beginning of the histology workflow. Designed for use with validated Leica Biosystems cassettes, the unit utilizes UV laser printing to generate markings, including barcodes and 2D codes, intended to remain clear and durable throughout processing and diagnostic review.

High-Speed Throughput and Workflow Automation

The instrument provides print speeds of up to 2.5 seconds per cassette and holds a capacity of up to 600 cassettes, which Leica Biosystems notes can help laboratories optimize turnaround times, prevent bottlenecks, and maintain workflow continuity under elevated demand.

By operating without ink and ribbons, the laser printer helps facilities lower total cost of ownership, reduce routine maintenance needs, and decrease instrument downtime, the company stated.

Leica
BIOSYSTEMS

The system also incorporates automated color recognition alongside laboratory information system (LIS) compatibility. These features match cassette colors to predefined templates, decreasing manual touchpoints and mitigating specimen labeling mistakes.

"Histology laboratories are often expected to do more with limited time, space and resources, while still needing confidence that every specimen is accurately identified across the diagnostic journey," says Anupama Mokkapati, senior vice president of core portfolio and global supply chain at Leica Biosystems, in a release. "The HistoCore Lightening C Laser Cassette Printer helps laboratories enhance foundational workflow steps by combining speed, durable print quality and seamless integration to support accurate, timely results to patients."

Front-End Traceability for Digital Pathology

As anatomic pathology laboratories increasingly adopt digital pathology platforms and artificial intelligence tools, front-end consistency and specimen tracking are critical for downstream imaging quality and diagnostic accuracy, according to Leica Biosystems.

Leica Biosystems, an operating company within Danaher, supports nearly 2 million cancer tests worldwide each week. The cassettes used with the instrument are intended for in vitro diagnostic use only.

The company plans to showcase the new system at the National Society for Histotechnology Convention in San Antonio, Texas, taking place Sept 25–29, 2026.

Photo caption: HistoCore LIGHTNING C Laser Cassette Printer
Photo credit: Leica Biosystems

Siemens Healthineers Launches CN-3000 and CN-6000 Hemostasis Analyzers in US

The automated platforms integrate four testing methodologies in a compact footprint and offer up to 13 hours of walkaway time for mid- and high-volume laboratories.

Siemens Healthineers announced that its CN-3000 and CN-6000 automated hemostasis analyzers are now available for patient testing in the US.



Designed for mid- and high-volume clinical laboratories, the systems consolidate clotting, chromogenic, immunoassay, and platelet aggregation testing methodologies onto a single platform that is up to 60% smaller than comparable systems currently on the market.

According to the company, hemostasis testing plays an essential role in clinical decision-making for surgery, anticoagulation therapy, and bleeding disorders by detecting abnormal blood clotting or bleeding. The CN systems support routine and specialty assays, enabling facilities to manage increasing workloads and high sample volumes within a smaller physical footprint.

"Streamlining complex workflows inherent to hemostasis testing allows labs to maximize productivity in a high-demand test category," says Michele Zwickl, head of laboratory solutions, Siemens Healthineers North America, in a release.

"The CN systems offer an efficiency trifecta:the ability to process more tests, deliver results faster, and reduce hands-on tasks, so that laboratory professionals can focus their expertise where it's needed most."

Automation and Extended Walkaway Time

To minimize manual intervention and routine instrument management, the analyzers incorporate automated features including predictive reagent management, automated repeat and reflex testing, advanced pre-analytical sample assessment, and onboard troubleshooting guidance, the company stated.

In addition, the systems offer large onboard reagent and consumable capacities that provide up to 13 hours of walkaway time.

The analyzers can also integrate with existing track-based laboratory automation and Atellica Data Manager, allowing health networks to access testing analytics, centralize instrument oversight, and standardize laboratory operations across multiple locations.

According to Siemens Healthineers, the CN-3000 and CN-6000 systems use common reagents, consumables, workflows, and user interfaces across multi-site health systems, which can generate operational cost efficiencies and standardize the testing experience. The instruments are also designed to maintain result correlation across the company's other hemostasis platforms as laboratory volume and testing demands grow.

Photo caption: Automated hemostasis analyzer
Photo credit: Siemens Healthineers

Nabsys Launches Tool to Analyze Genetic Repeat Expansions Linked to Inherited Disorders



New software allows researchers to examine repeat expansions associated with up to 23 disease-related genetic regions in a single run.

Nabsys has released RepX, a repeat expansion analysis pipeline available through its Nabsys Navigator cloud platform. The software uses Electronic Genome Mapping (EGM) data collected on the OhmX platform to investigate disease-associated repeat expansions, offering the capacity to analyze up to 23 loci in a single run.

Repeat expansions are linked to numerous inherited disorders but have historically proven difficult for laboratories to characterize. EGM analyzes individual ultra-long DNA molecules without amplification or ligation, eliminating common preparation biases and allowing researchers to evaluate the distribution of expansion sizes and examine repeat instability within each allele.

"Repeat expansion research benefits from understanding not just expansion size, but how it varies within an allele," says Barrett Bready, MD, founder and CEO of Nabsys, in a release. "RepX pairs those EGM single-molecule insights with the potential for low-cost, multi-locus analysis—advancing our goal of making single-molecule genomics accessible to every lab."

Integration Across Genomic Data Sets

RepX operates on data generated using the standard OhmX VOLT Whole Genome Kit, meaning the same dataset can simultaneously support genome-wide structural variant and copy number variant analyses.

Within the Nabsys Navigator platform, the new pipeline joins SV-Discover for genome-wide structural variant analysis and SV-Verify for confirming structural variants identified by other technologies, backed by integrated visualization tools.


Demonstrations at ASHG 2026

Nabsys will demonstrate RepX and Nabsys Navigator at the American Society of Human Genetics (ASHG) 2026 Annual Meeting in Montreal, Canada.

During the conference, the company will present five posters highlighting applications of EGM technology. The scheduled presentations include a study detailing CRISPR/Cas9 customization of EGM repeat expansion assays presented by Kasra Tabatabaei, PhD, and a Reviewers' Choice poster examining CRISPR/Cas9 optimization presented by John Thompson, PhD.

The OhmX platform, Nabsys Navigator, and RepX are designated for research use only and are not for use in diagnostic procedures.

Delve Bio Launches Blood Test That Can Detect More Than 68,000 Pathogens



The new test uses metagenomic sequencing to identify bacteria, viruses, fungi, and parasites from a single blood sample, with results available the next day.

Delve Bio has launched Delve Detect Plasma, a blood-based metagenomic next-generation sequencing (mNGS) assay that enables unbiased detection of more than 68,000 bacteria, fungi, DNA and RNA viruses, and parasites with next-day results. The company introduced the assay and presented accompanying clinical utility data at IDWeek 2026 in Washington, DC.

The assay is the second in Delve Bio's commercial portfolio, following Delve Detect CSF, which was developed for patients with suspected meningitis or encephalitis. By expanding into plasma, the company applies its proprietary Delve Decide mNGS technology to an accessible sample type, analyzing both DNA and RNA from a single blood draw to identify organisms against a curated database.

Testing is performed in a CLIA-certified, CAP-accredited laboratory, with results delivered the day after sample receipt.

"For complex cases where patients are receiving broad and empiric therapies, getting the right answer quickly can inform treatment decisions and get patients on the most appropriate therapy sooner," says Brad Murray, founder and CEO of Delve Bio, in a release. "Clinicians need a more comprehensive, cost-effective way to look for causes of infections without relying on multiple cycles of targeted testing. Delve Detect Plasma brings our proven metagenomic sequencing approach to a simple blood sample, providing a more complete view of potential pathogens with DNA or RNA genomes within a clinically relevant timeframe."

Clinical Data Presented at IDWeek 2026

At IDWeek 2026, Delve Bio and research collaborators are presenting three scientific studies demonstrating mNGS diagnostic performance in challenging clinical cases. The presentations highlight the test's capability to identify neuroinvasive arboviruses, subtype enterovirus in central nervous system infections, and detect neurotropic astrovirus strains in immunocompromised patients.

"The advantage of metagenomic sequencing is that we don't have to know exactly what we're looking for before we start testing," says Charles Chiu, MD, PhD, cofounder of Delve Bio and professor of laboratory medicine at the University of California, San Francisco, in a release.

"This approach can be especially valuable in complex cases, where evaluating a wider range of potential causes of infection may help us identify something that conventional testing could miss. With Delve Detect Plasma, critically ill patients with systemic infections can now be tested with our mNGS platform through a simple blood draw."

Diagnostic Scope and Clinical Support

Standard infectious disease diagnostic workflows often require clinicians to suspect specific candidate organisms in advance, which can prompt multiple rounds of targeted testing while patients remain on empiric antimicrobial therapy.



Delve Bio's platform uses a **pathogen-agnostic sequencing method** designed to detect both common and rare infectious agents from a single test order.

The Delve Detect service includes access to the Clinical Microbial Sequencing Board, an on-call team of infectious disease and laboratory medicine experts who provide clinical context for results.

ID 78343383 © Kts | Dreamstime.com

Werfen Launches Web-Based Autoimmune Data Management Platform



The browser-based Quanta Link 5.0 system centralizes autoimmune testing data across instruments and connects with laboratory information systems.

Werfen has announced the global launch of Quanta Link 5.0, an updated data management platform designed to centralize and simplify **autoimmune testing workflows** in clinical laboratories.

The platform transitions to an HTML-based interface, allowing laboratory professionals to access the system through a standard web browser without requiring local software installations. This setup provides greater flexibility in how and where staff interact with the platform while supporting evolving clinical demands for digitalization, IT alignment, and cybersecurity readiness.

To support high-volume laboratories managing testing complexity, Quanta Link 5.0 introduces standardized workflows and increased automation to reduce manual handling steps. The update also preserves validated workflows to ensure operational continuity, instrument integration, and laboratory information system connectivity for current users.

"Quanta Link 5.0 reflects our commitment to delivering solutions that are both powerful and easy to use in real-world autoimmune laboratory settings," says Vijay Namasivayam, PhD, chief operating officer, autoimmunity, in a release. "By combining a modern, flexible user experience with meaningful workflow improvements, we are helping laboratories operate more efficiently while continuing to support clinicians in delivering high-quality patient care."

Centralized Multi-Instrument Integration

The platform functions as a central hub for autoimmune diagnostics, integrating results across diverse systems—including **Aptiva**, Bio–Flash, Quanta-Lyser 3000, Nova View, and manual microscopy—into a single interface.

Centralizing these data streams is intended to streamline result processing, enhance specimen and test traceability, and support consistent data interpretation across laboratory operations.

The system also includes flexible configuration options that enable facilities to adapt operational parameters to their specific workflow needs. Quanta Link 5.0 is available immediately to **Werfen** customers worldwide.

Photo caption: Quanta Link 5.0
Photo credit: Werfen

OGT Unveils SureSeq NGS Automation Compatible with Hamilton NGS STAR Line



The automated workflows **aim to** reduce hands-on time, increase sample throughput, and streamline library preparation for clinical research laboratories. OGT has introduced next-generation sequencing (NGS) automation capabilities across its **SureSeq NGS portfolio**, offering compatibility with the **Hamilton NGS STAR Line**. The system is designed to help laboratories optimize resources, manage increasing sample volumes, and meet turnaround time targets. Developed in collaboration with laboratory partners and workflow specialists, the automation-enabled SureSeq workflows remove manual intervention during the most time-consuming stages of NGS library preparation. By minimizing hands-on requirements, the platform supports high-throughput processing across multiple sample types while delivering more consistent results and greater process reproducibility.

"NGS automation is essential for high-volume labs to get the most out of their NGS analysis," says Adrian Smith, CEO of OGT, in a release. "By removing labour-intensive manual steps, labs can dramatically increase capacity, improve reproducibility and consistency allowing them to focus their teams where it matters most."

Addressing Laboratory Bottlenecks

As sample volumes continue to increase, clinical research laboratories face growing pressure to maintain high throughput while handling labor-intensive library preparation protocols. Manual steps during these workflows can create operational bottlenecks and increase the risk of variability between runs.

The automated workflows integrate with OGT's portfolio of **hematological malignancy-focused** SureSeq NGS panels, including the recently introduced **SureSeq Myeloid MRD Plus NGS Panel**.

This combination is intended to provide clinical research laboratories with the throughput, consistency, and analytical capacity needed to scale their genomic operations effectively without adding resource burden.

Photo caption: SureSeq NGS
Photo credit: OGT

Thermo Fisher Scientific Introduces Gibco CHO-K1 Catalog Panel to Boost Biologics Titer and Cell Density



The cGMP-ready media and feed panel demonstrated up to 73% higher titer and 202% higher viable cell density in fed-batch study evaluations.

Thermo Fisher Scientific has launched the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to support cell growth and protein production across CHO-K1 cell lines.

Available in both liquid and dry powder media formats, the panel offers options for **biologics** and **biosimilars** developers working across upstream process development, scale-up, and manufacturing workflows.

Product Launches

The formulations are chemically defined and animal origin-free to help teams address regulatory considerations and establish reliable supply assurance.

"Biologics developers need flexible solutions that help them move quickly while maintaining confidence in process performance and scalability," says Alex Cherkassky, vice president and general manager of Thermo Fisher Scientific's cell culture business, in a release.

"With the Gibco CHO-K1 Catalog Panel, teams have access to multiple media and feed options that can help them identify high-performing combinations while supporting productivity, product quality and progression toward scalable manufacturing."

Study Results and Evaluation Performance:

In a 14-day fed-batch study utilizing a CHO-K1 GS cell line, select combinations from the catalog panel demonstrated significant performance gains compared with benchmark catalog media and feeds tested.

According to study data, the panel achieved:

1. Up to 73% higher titer compared with benchmark catalog media and feeds tested
2. Up to 202% higher peak viable cell density compared with the benchmark products tested
3. Strong product quality performance across evaluated conditions

Workflow Optimization and Scale-Up

Upstream development teams frequently evaluate diverse media and nutrient feeds to establish optimal conditions for specific cell lines. The panel comprises multiple ready-to-use basal media and feed combinations to help developers rapidly identify high-performing pairings, accelerate evaluation timelines, and support transition into scalable biomanufacturing. The products are designated for research use only and are not for use in diagnostic procedures.



Elevate Your Reading Experience

Subscribe to our magazine and delve into a world of insightful articles, captivating stories, and expert opinions. With each issue, you'll explore new perspectives, stay informed, and indulge in high-quality content curated just for you.

#microbiozindia

SCIZORA™

THE SCIENTIST-LED B2B PROCUREMENT PLATFORM FOR PHARMA QC SOLUTIONS





Where Pharmaceutical Science Drives Smarter Procurement

Scizora connects QC Scientists, trusted product reviews and equipment manufacturers to build **KOL influence**, generate **qualified leads** and **accelerate sales.**

QC SCIENTISTS

Explore. Review. Recommend.

Share real-world experiences and help the industry make better decisions.

FOR QC SCIENTISTS

Discover Solutions
Search and compare a wide range of QC equipment and consumables.

Share Experiences
Write reviews and ratings based on real laboratory use and performance.

Make Better Decisions
Access authentic insights to choose the right solutions with confidence.



FOR MANUFACTURERS

Increase Brand Visibility
Showcase your products to a highly targeted scientific audience.

Engage KOLs
Collaborate with key opinion leaders who influence purchasing decisions.

Generate Qualified Leads
Drive high-quality leads and accelerate your sales pipeline.

INFLUENCE & KOL NETWORK

Identify key opinion leaders and build credibility through authentic scientific insights.

MANUFACTURERS

Build brand influence, engage KOLs and generate qualified leads that drive measurable results.

QUALIFIED ENGAGEMENT. REAL RESULTS.

From trusted reviews to qualified leads – empowering smarter procurement decisions.

ONE PLATFORM. MULTIPLE BENEFITS.

TRUSTED REVIEWS
Verified reviews from pharma QC scientists you can trust.

VERIFIED USERS
Exclusive platform for pharma professionals and manufacturers.

SCIENCE-DRIVEN
Decisions powered by data, experience and scientific expertise.

STRONGER CONNECTIONS
Meaningful engagement between scientists and solution providers.

BETTER CONVERSIONS
Turn influence into opportunities and opportunities into growth.

PRIVACY & SECURITY
Your data and identity are protected with highest standards.

DISCOVER. REVIEW. INFLUENCE. PROCURE.

For Pharma. By Scientists. | For Smarter Science. | For Better Business.

Scizora™ is a brand introduced by

Microbioz®

Microbioz India is a leading B2B media and information platform for the pharmaceutical, bio-pharma, laboratory and analytical industries.

www.scizora.com

connect@scizora.com

PrimeDx™

High-purity raw materials for Diagnostic Innovation

As diagnostic technologies evolve, manufacturers need dependable access to critical raw materials that support consistent formulation and production. **PrimeDx™** by **SRL** is a specialized raw material portfolio created to support the evolving needs of the **diagnostic kit manufacturers and molecular biology industries**. With a broad selection of high-purity components across multiple categories, PrimeDx™ helps manufacturers build a reliable foundation for **diagnostic reagent development, manufacturing and scale-up**.



The Right Chemistry for Reliable Diagnostic Kits

- High Purity
- Low Endotoxin & Low Metal Content
- Lot-to-Lot Consistency
- Contamination-Free Packaging

Critical raw materials for Diagnostic Kit Formulation

62560	Albumin Bovine (BSA) (pH 7) fraction V PrimeDx, 98%
19575	Casein acc. to Hammarsten, PrimeDx, 95% Protein
11077	Sodium Azide PrimeDx, 99%
56489	Tris Buffer PrimeDx, 99.9%
64762	EDTA Disodium Salt Dihydrate PrimeDx, 98%
86561	ß-Nicotinamide Adenine Dinucleotide (Oxidized) (ß-NAD, DPN) PrimeDx, 98%

... and many more

Applications

Clinical Chemistry | Immunoassay | Hematology | Coagulation
Microbiology | Molecular Diagnostics | Serology | Rapid Testing

Explore the PrimeDx™ range
for your critical reagent requirements

Sisco Research Laboratories
marketing@srlchem.com
+91 22-42685800

Subscribe now !!



microbiozhealth.com

support@microbiozindia.com

TECHNOCARE MEDISYSTEMS

TRUSTED COMPANY IN **MEDICAL INNOVATION** SINCE 2001

We proudly offer the lowest prices in India, guaranteed—without compromising on quality. Our mission is simple:

"TO PROVIDE QUALITY MATERIAL AND THE BEST SERVICE."

For orders and inquiries, contact:

POOJA DHADUK

+91 95374 17749



Multipara Monitor



Multipara Monitor



SYRINGE INFUSION PUMP



SYRINGE INFUSION PUMP



ECG MACHINE-TM-3E



ECG MACHINE-TM-1201



ECG MACHINE TM-302



ECG MACHINE TM-12E



FETAL MONITOR



PHOTOTHERAPHY & BABY WARMER & BABY WEIGHT SCALE



VAIN FINDER



MONITOR STAND AND TROLLEY



JAUNDICE METER



PULSE OXIMETER



PULSE OXIMETER



RESPIRATORY PRODUCTS



BIPAP



FOGGER MACHINE AND FUMIGATOR



DEFIBRILLATOR AND AED



AED

- DVT PUMP
- FETAL DOPPLER
- 3CH, 12CH HOLTER RECORDER
- AMBULATORY BP MONITOR
- SPIROMETER
- video laryngoscpes
- PATIENT WARMER WITH BLANCKETS AND TROLLEY
- BLOOD/FLUID WARMER
- VIDEO LARYNGOSCOPE
- VENTILATOR
- ORTHO DRIL
- OXYGEN CONCERNTRATOR
- CAUTERY MACHINE
- DIGITAL TOURNIQUET
- EMERGENCY AMBULANCE TROLLEY
- COMPITABLE SPO2 SENSOR
- FETAL MONITOR
- BIPAP
- HD/NON-HD VIDEO COLPOSCOPE
- INTENSIVE CARE SERVO WARMER
- DIGITAL BABY SCALE
- SUCTION MACHINE
- ETCO2 MONITOR
- FOGGER MACHINE
- FUMIGATOR
- STANDS AND TROLLEY

Address:-C-1310/1311, New Bombay Market, Umarwada, Surat-395010
Email:technocare9@Gmail.Com

PUBLISHED ON: 25th OCTOBER 2026 RNI NUMBER: UPENG/2017/73675

AKAS® INFUSIONS



PRECISION **DELIVERED**

At AKAS Infusions, we believe that accuracy and reliability define exceptional patient care. Our wide range of infusion solutions is designed to meet diverse medical needs with seamless delivery and advanced technology.

Hello
Helps to prevent Deep Vein Thrombosis

AKAS® INFUSIONS

WARMJET
Blood and Fluid Warmer

Made in India. Made for the World.

AKAS Medical Equipment,
SP127, 1st Main road, Ambattur
Industrial Estate, Chennai 600058

+91-98403 79116
sales@akasinfusions.com
www.akasinfusions.com

CE 1023